Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer (FREE)

By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH Biosimilar trastuzumab appears to have a similar effect on HER2-positive, early-stage breast cancer as standard trastuzumab (Herceptin), according …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news